Alan W. Milinazzo, the President and CEO of InspireMD, Inc. (NSPR), Interviews with The Wall Street Transcript
67 WALL STREET, New York - March 17, 2014 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Affordable Care Act - Aging U.S. Population - End Market Improvement - Biotech, Pharma and Medical Device Convergence - Changing Competitive Dynamics
Companies include: InspireMD, Inc. (NSPR) and many more.
In the following excerpt from the Medical Devices Report, the President and CEO of InspireMD, Inc. (NSPR) discusses company strategy and the outlook for this vital industry:
TWST: Can you describe your technology, and where it is in the regulatory process?
Mr. Milinazzo: Our MicroNet technology is quite straightforward. We take traditional stents used for interventional procedures and attach MicroNet proprietary mesh technology that allows the stent to serve a dual purpose: to open a blocked artery as intended, but to also allow the stent to trap any material that could be dislodged during that stent deployment. This is a common problem as blood clots and plaque debris can cause unintended consequences, such as heart attacks, strokes and even death.
So our technology takes current stent designs and improves on them by adding this very unique MicroNet mesh, which is a very fine polyethylene material that is fully biocompatible. It is attached to these stents and used for two equally important reasons: to open the vessel and also for embolic protection, i.e., trapping the debris that can be dislodged as a result of reopening a blocked artery.
TWST: You mentioned some of this, but just in comparison to what else is out there, what do you deem the advantages of this technology?
Mr. Milinazzo: In a coronary application for heart attack patients - also known as AMI patients, acute myocardial-infarction patients - physicians try to deal with this potential embolic event issue by using another device, such as an aspiration catheter, where they literally try to suck out some of this clot or plaque. They may also use other devices, such as a filter. Currently, they need to put a second device in the artery and capture this debris.
Our technology essentially takes what physicians are doing today, which is a two-step process and makes it a one-step process. That's the major advantage: It saves time, and it saves money for the physician and for the hospital, and early results indicate, it also greatly improves the patient's clinical outcome...
For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
